TY - JOUR
T1 - Direct Immunodetection of Global A-to-I RNA Editing Activity with a Chemiluminescent Bioassay
AU - Knutson, Steve D.
AU - Arthur, Robert A.
AU - Johnston, H. Richard
AU - Heemstra, Jennifer M.
N1 - Funding Information:
This work was supported by the National Institutes of Health (R21GM134564, and R01GM140657 to J.M.H.). This study was supported in part by the Emory Integrated Genomics Core (EIGC), which is subsidized by the Emory University School of Medicine and is one of the Emory Integrated Core Facilities. We would also like to thank Christopher Wojewodzki for his helpful advice and technical expertise in ELISA development, Heather Hundley for her expertise in epitranscriptomics, and Viren Patel for his help in computational analysis.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
PY - 2021/7/26
Y1 - 2021/7/26
N2 - Adenosine-to-inosine (A-to-I) editing is a conserved eukaryotic RNA modification that contributes to development, immune response, and overall cellular function. Here, we utilize Endonuclease V (EndoV), which binds specifically to inosine in RNA, to develop an EndoV-linked immunosorbency assay (EndoVLISA) as a rapid, plate-based chemiluminescent method for measuring global A-to-I editing signatures in cellular RNA. We first optimize and validate our assay with chemically synthesized oligonucleotides. We then demonstrate rapid detection of inosine content in treated cell lines, demonstrating equivalent performance against current standard RNA-seq approaches. Lastly, we deploy our EndoVLISA for profiling differential A-to-I RNA editing signatures in normal and diseased human tissue, illustrating the utility of our platform as a diagnostic bioassay. Together, the EndoVLISA method is cost-effective, straightforward, and utilizes common laboratory equipment, offering a highly accessible new approach for studying A-to-I editing. Moreover, the multi-well plate format makes this the first assay amenable for direct high-throughput quantification of A-to-I editing for applications in disease detection and drug development.
AB - Adenosine-to-inosine (A-to-I) editing is a conserved eukaryotic RNA modification that contributes to development, immune response, and overall cellular function. Here, we utilize Endonuclease V (EndoV), which binds specifically to inosine in RNA, to develop an EndoV-linked immunosorbency assay (EndoVLISA) as a rapid, plate-based chemiluminescent method for measuring global A-to-I editing signatures in cellular RNA. We first optimize and validate our assay with chemically synthesized oligonucleotides. We then demonstrate rapid detection of inosine content in treated cell lines, demonstrating equivalent performance against current standard RNA-seq approaches. Lastly, we deploy our EndoVLISA for profiling differential A-to-I RNA editing signatures in normal and diseased human tissue, illustrating the utility of our platform as a diagnostic bioassay. Together, the EndoVLISA method is cost-effective, straightforward, and utilizes common laboratory equipment, offering a highly accessible new approach for studying A-to-I editing. Moreover, the multi-well plate format makes this the first assay amenable for direct high-throughput quantification of A-to-I editing for applications in disease detection and drug development.
KW - RNA
KW - adenosine-to-inosine editing
KW - bioorganic chemistry
KW - chemiluminescence
KW - immunoassays
UR - http://www.scopus.com/inward/record.url?scp=85108951212&partnerID=8YFLogxK
U2 - 10.1002/anie.202102762
DO - 10.1002/anie.202102762
M3 - Article
C2 - 33979483
AN - SCOPUS:85108951212
SN - 1433-7851
VL - 60
SP - 17009
EP - 17017
JO - Angewandte Chemie - International Edition
JF - Angewandte Chemie - International Edition
IS - 31
ER -